SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024213
Filing Date
2020-05-11
Accepted
2020-05-11 16:17:52
Documents
55
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20200331.htm   iXBRL 10-Q 1911736
2 EX-31.1 fate-ex311_6.htm EX-31.1 9823
3 EX-32.1 fate-ex321_7.htm EX-32.1 4865
  Complete submission text file 0001564590-20-024213.txt   7864366

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fate-20200331.xsd EX-101.SCH 49485
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20200331_cal.xml EX-101.CAL 43447
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20200331_def.xml EX-101.DEF 189674
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20200331_lab.xml EX-101.LAB 425589
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20200331_pre.xml EX-101.PRE 312070
54 EXTRACTED XBRL INSTANCE DOCUMENT fate-10q_20200331_htm.xml XML 1706948
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 20865028
SIC: 2836 Biological Products, (No Diagnostic Substances)